RDN Outperforms Industry, Trades Near 52-Week High: Time to Buy?

Radian Group (market cap $4.86B) is trading near its 52-week high ($35.92 close vs $38.84 high) with shares above the 50- and 200-day SMAs and a P/B of 1.05x versus industry 2.71x. Zacks projects 2025 EPS +4.3% with 2026 EPS and revenue growth of ~5% and 9.6%, a four-quarter earnings surprise streak averaging +12.15%, and a consensus target of $39.17 (≈7.9% upside). Management agreed to acquire Inigo Limited in a primarily all-cash $1.7B deal expected to close early 2026 that Radian says will double annual revenue and drive mid-teens EPS growth and ~200 bps ROE improvement in the first full year post-close; RDN also cites improving claims trends, stronger capital position, ROIC of 6.75% (TTM) and a 2.8% dividend yield after a 4.1% quarterly increase in Q1 2025.

Analysis

Market structure: Radian (RDN) is the direct beneficiary of both a structurally improving MI (mortgage insurance) loss trend and the announced $1.7bn Inigo acquisition that diversifies revenue into specialty lines, which should raise pricing power vs pure-play peers (MGIC-like peers) over 12–24 months. Competitors (larger life insurers MET, PRU) are largely unaffected or disadvantaged on niche MI economics; reinsurers and specialty brokers pick up business. On rates/credit, a higher-rate regime that reduces refinancing increases policy duration and can depress new purchase-volume premium flow by mid-single digits annually, while corporate credit spreads on RDN could widen if leverage rises materially.

Risk assessment: Key tail risks are integration failure or synergy shortfalls (>200bps ROE miss), a forced >$1bn equity raise (dilution >20%), or a housing shock that reverses the declining-claim trend (e.g., 150–200bps national mortgage delinquency uptick). Immediate risk (days) is volatility around deal/earnings headlines; short-term (3–12 months) is rating/financing execution; long-term (12–36 months) is realization of mid‑teens EPS growth. Hidden dependencies include reinsurance counterparty capacity and RMBS market liquidity.

Trade implications: Tactical: establish a 2–3% long RDN position size now (target $39–45 in 6–12 months), add on pullback to <$32 (≈10% drop), set initial stop-loss at 12–15%. Options: buy a 9–15 month 35/45 call spread to capture post-close EPS leverage while capping premium. Relative value: pair long RDN vs short MET or PRU (dollar‑neutral) for 6–12 months to capture mortgage-specific outperformance.

Contrarian angles: Consensus assumes smooth integration and mid‑teens EPS upside; that may be optimistic given purchase price ~35% of market cap and “primarily cash” financing—capital strain risk is underpriced. Historical parallels (MI firms that diversifed without capital increases) show multi-year underperformance if goodwill and financing costs rise. Watch for dividend/buyback cuts as an early warning sign.

Key Decisions for Investors

• Establish a 2–3% long position in RDN (buy $34–36 tranche), target $39–45 within 6–12 months; add to position if RDN falls below $32 (≈10% drawdown).
• Execute a 9–15 month RDN 35/45 call spread (buy 35c, sell 45c) sized to cap cost to <0.5% portfolio risk; exit if spread value doubles or if acquisition financing disclosure shows >$1bn incremental debt or >10% equity issuance.
• Enter a dollar‑neutral pair trade: long RDN vs short MET or PRU (equal dollar exposure) for 6–12 months to capture mortgage‑specific tailwinds; trim if RDN underperforms by 15% or if MET/PRU announce idiosyncratic capital returns.
• Limit exposure if Radian announces capital raise >$500M or if regulatory filings show a deterioration in statutory capital/risk‑to‑capital ratio >200bps; reduce position by 50% upon such trigger within 30 days.
• Monitor weekly: claim filings, insured delinquency rates, reinsurance counterparty ratings, and S&P/Fitch comments—if claim trend reverses (30‑day delinquencies rise >25% quarter‑over‑quarter) move to neutral within 5 trading days.